Ua loiloi nā kānaka ʻepekema mai nā hui ʻelua i ke ʻano o ka SARS-CoV-2 Omicron variant, nā ʻano viral i koho ʻia, a me nā clones plasmid i hoʻolālā ʻia. Manaʻo mākou hiki ke hoʻonui ʻia nā kano ʻokoʻa Omicron SARS-CoV-2 hou i loko o ka hoʻokolohua lapaʻau ma lalo o 100 mau lā.
"Ke manaʻoʻiʻo nei mākou he mea nui ka hoʻomohala ʻana i nā kano hou i ka wikiwiki a me ka maikaʻi e hakakā i ka ʻano hou Omicron COVID-19. E hana pū mākou me nā kino hoʻoponopono a ʻimi i nā noiʻi lapaʻau kūpono a me nā ʻae kānāwai e lawe mai i kēia kano i ka mākeke i ka hiki ke hiki. wahi a Brad Sorenson, Luna Nui o Providence Therapeutics.
"Ke kakali nei mākou i ka hoʻomohala wikiwiki ʻana i kēia kano ʻano Omicron hou me Providence, a me ka lawe ʻana i ka pōmaikaʻi o kēia kano i kēlā mau wahi me ka haʻahaʻa haʻahaʻa i nā lāʻau lapaʻau mRNA o kēia manawa." Ua ʻōlelo ʻo Kerry Blanchard, MD, PhD, Luna Nui o Everest Medicines.
He aha e lawe ʻia mai kēia ʻatikala:
- “We look forward to rapidly developing this new Omicron variant vaccine with Providence, and bringing the benefit of this vaccine to those areas with lower accessibility to current mRNA vaccine treatments in particular.
- “We believe it is essential to develop new vaccines quickly and effectively to combat the new Omicron COVID-19 variant.
- We will work closely with regulatory bodies and seek the appropriate clinical studies and regulatory approvals to bring this vaccine to market as soon as possible.
